CHRNA7 Gene

CHRNA7 Gene

Introduction

Chrna7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

<div class="infobox infobox-gene"> [@supsup2026a]
<table> [@supsup2026b]
<tr><th colspan="2" style="background:#4477AA; color:white; text-align:center">CHRNA7</th></tr> [@supsup2015]
<tr><th>Full Name</th><td>Cholinergic Receptor Nicotinic Alpha 7 Subunit</td></tr> [@supsup2019]
<tr><th>Chromosome</th><td>15q13.3</td></tr> [@supsup2011]
<tr><th>NCBI Gene ID</th><td>[1139](https://www.ncbi.nlm.nih.gov/gene/1139)</td></tr> [@supsup2009]
<tr><th>OMIM</th><td>[100511](https://www.omim.org/entry/100511)</td></tr> [@supsup2012]
<tr><th>Ensembl ID</th><td>ENSG00000175344</td></tr>
<tr><th>UniProt ID</th><td>[P36544](https://www.uniprot.org/uniprot/P36544)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Epilepsy, Rett Syndrome</td></tr>
</table>
</div>

Function

CHRNA7 Gene

Introduction

Chrna7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

<div class="infobox infobox-gene"> [@supsup2026a]
<table> [@supsup2026b]
<tr><th colspan="2" style="background:#4477AA; color:white; text-align:center">CHRNA7</th></tr> [@supsup2015]
<tr><th>Full Name</th><td>Cholinergic Receptor Nicotinic Alpha 7 Subunit</td></tr> [@supsup2019]
<tr><th>Chromosome</th><td>15q13.3</td></tr> [@supsup2011]
<tr><th>NCBI Gene ID</th><td>[1139](https://www.ncbi.nlm.nih.gov/gene/1139)</td></tr> [@supsup2009]
<tr><th>OMIM</th><td>[100511](https://www.omim.org/entry/100511)</td></tr> [@supsup2012]
<tr><th>Ensembl ID</th><td>ENSG00000175344</td></tr>
<tr><th>UniProt ID</th><td>[P36544](https://www.uniprot.org/uniprot/P36544)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Epilepsy, Rett Syndrome</td></tr>
</table>
</div>

Function

The nicotinic [acetylcholine](/entities/acetylcholine) receptor alpha 7 (α7 nAChR) is a homomeric ligand-gated ion channel highly expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. α7 nAChR exhibits high calcium permeability and rapidly desensitizes upon agonist binding. It plays crucial roles in cognitive functions including attention, memory, and learning. In Alzheimer's disease, α7 nAChR density is reduced in the hippocampus, and the receptor interacts with [amyloid-beta](/proteins/amyloid-beta), contributing to synaptic dysfunction. Agonists of α7 nAChR (including nicotine) have shown promise in preclinical models for enhancing cognition and providing neuroprotection.

Gene Structure

The CHRNA7 gene spans approximately 45 kb on chromosome 15q13.3 and consists of 10 exons. The gene encodes a protein of 502 amino acids. Alternative splicing produces multiple transcript variants, with the canonical isoform being the most widely expressed. The promoter region contains binding sites for multiple transcription factors including SP1, AP2, and [NF-κB](/entities/nf-kb), suggesting regulation by neuronal activity and inflammatory signals.

Protein Structure

The α7 nAChR is a pentameric ligand-gated ion channel composed of five identical α7 subunits. Each subunit contains:

• Extracellular N-terminal domain: Contains the ligand-binding site at the interface between subunits
• Transmembrane domains (M1-M4): Four α-helical transmembrane segments that form the ion channel pore
• Intracellular loop: Between M3 and M4, contains sites for post-translational modifications
• C-terminal domain: Short cytoplasmic tail

Expression Pattern

Central Nervous System

• [Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 pyramidal [neurons](/entities/neurons) and dentate gyrus granule cells
• [Cortex](/brain-regions/cortex): Layer-specific expression, highest in layers II-III and V
• Basal ganglia: Moderate expression in striatum and nucleus accumbens
• Thalamus: Specific nuclei show expression
• Olfactory bulb: High expression in mitral and tufted cells

Peripheral Expression

• Autonomic ganglia
• Immune cells (macrophages, T-cells)
• Sensory neurons
• Pineal gland

Molecular Mechanisms

Signal Transduction

Key Interactions

• Aβ interaction: α7 nAChR binds amyloid-beta with high affinity, leading to receptor internalization and dysfunction
• JNK pathway: Activation leads to [apoptosis](/entities/apoptosis)
• GABAergic modulation: α7 nAChR on interneurons modulates inhibition

Role in Neurodegeneration

Alzheimer's Disease

• Receptor loss: 30-50% reduction in α7 nAChR density in AD hippocampus
• Aβ interaction: Aβ1-42 binds α7 nAChR, disrupts signaling and promotes toxicity
• Calcium dysregulation: Loss of α7 function contributes to calcium homeostasis failure
• Cognitive decline: Correlates with memory deficits

Parkinson's Disease

• Nigrostriatal involvement: α7 nAChR on dopaminergic neurons may be affected
• Neuroprotection: Nicotinic agonists show protective effects in PD models
• Levodopa-induced dyskinesias: α7 nAChR antagonists may reduce dyskinesias

Other Neurological Disorders

• Schizophrenia: CHRNA7 copy number variations and expression changes
• Rett Syndrome: MECP2 regulates CHRNA7 expression
• Epilepsy: Altered expression in epileptic tissue

Therapeutic Implications

Agonists

Positive Allosteric Modulators (PAMs)

• Enhance agonist efficacy without directly activating
• Fewer side effects than direct agonists
• Examples: CCMI, LY2087101

Antagonists

• Used to study receptor function
• Methyllycaconitine (MLA) is a selective antagonist

Animal Models

• CHRNA7 knockout mice: Show learning deficits, reduced hippocampal plasticity
• α7 overexpressing mice: Enhanced cognition, neuroprotection against Aβ
• Transgenic AD models: Crossbreeding with α7 mutants reveals interaction

Clinical Trials

Several clinical trials have evaluated α7 nAChR agonists:

• EVP-6124: Phase II showed cognitive improvement in AD
• RG3487: Phase II for schizophrenia
• A-582941: Phase I completed

Background

The study of Chrna7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NCBI Gene Database](https://www.ncbi.nlm.nih.gov/gene/1139)
• [UniProt Protein Database](https://www.uniprot.org/uniprot/P36544)
• [Ensembl Genome Browser](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175344)
• [IUPHAR Database: α7 nAChR](https://www.guidetopharmacology.org/GTOR7-1.xml)

Pathway Diagram

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication](/hypothesis/h-a4e259e0) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: CHRNA7

Pathway Diagram

The following diagram shows the key molecular relationships involving CHRNA7 Gene discovered through SciDEX knowledge graph analysis:

Disease Associations

Source: Open Targets Platform (opentargets.org)

| Disease | Association Score | Disease ID |
|--------|-------------------|------------|
| Alzheimer disease | 0.3713 | MONDO_0004975 |
| neurodegenerative disease | 0.3520 | EFO_0005772 |
| Increased total eosinophil count | 0.3137 | HP_0001880 |
| Abnormality of limbs | 0.3137 | HP_0040064 |
| schizophrenia | 0.3125 | MONDO_0005090 |